Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03. Januar 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P....
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
16. Dezember 2022 08:10 ET
|
Amicus Therapeutics, Inc.
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with...
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
15. November 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New...
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
07. November 2022 12:20 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
07. November 2022 07:00 ET
|
Amicus Therapeutics, Inc.
Year-to-Date 2022 Reported Revenue Growth of 8% (16% at CER) On-Track to Deliver Full-Year 2022 Double-Digit Revenue Growth of 15-20% at CER Advancing Launch Preparation for AT-GAA in Pompe Disease...
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
28. Oktober 2022 16:01 ET
|
Amicus Therapeutics, Inc.
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date Company is Now Actively Engaged...
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
27. Oktober 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at...
Amicus Therapeutics Announces Participation at World Muscle Society 2022
11. Oktober 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included...
Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting
21. September 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be...
Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
08. September 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global...